- Home
- ASRT vs MNOV Comparison
ASRT vs MNOV Comparison
Compare ASRT & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASRT | MNOV |
|---|---|---|
| Founded | 1995 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.0M | 69.4M |
| IPO Year | 2004 | 2004 |
Fundamental Metrics
Financial Performance| Metric | ASRT | MNOV |
|---|---|---|
| Price | $23.45 | $1.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $18.00 | $7.50 |
| AVG Volume (30 Days) | ★ 408.0K | 17.3K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $118,713,000.00 | $2,360,807.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.85 | $180.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $0.60 | $1.17 |
| 52 Week High | $23.46 | $1.96 |
Technical Indicators
Market Signals| Indicator | ASRT | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 87.60 | 45.16 |
| Support Level | $0.70 | $1.35 |
| Resistance Level | N/A | $1.43 |
| Average True Range (ATR) | 0.19 | 0.03 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 99.71 | 8.70 |
Price Performance
Historical ComparisonAbout ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.